drugset / Trial / NCT00569153
Safety Study of TAK-700 in Subjects With Prostate Cancer.
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients with asymptomatic metastatic, androgen independent prostate cancer.
Timeline
- Start
- 2008-04
- Primary completion
- 2013-01
- Completion
- 2013-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orteronel | Small molecule | 300 mg | Oral |
| Subject | Orteronel | Small molecule | 400 mg | Oral |
| Subject | Orteronel | Small molecule | 600 mg | Oral |